The results of the phase 2/3 TeenCOVE study in more than 3,700 adolescents aged 12 to 17 revealed no cases of COVID-19 after two doses of the mRNA-1273 shot, giving it a top-line efficacy of 100% in this age group.
The results were in line with the adult COVE study, which formed the basis for an emergency use authorisation (EUA) for Moderna’s vaccine in December 2020. The primary endpoint was non-inferior immunogenicity compared to the COVE data set.
